Citius Pharmaceuticals, Inc.

Key facts

Headquarters

Cranford, New Jersey, United States

Employees

Unknown

Industries

Biopharma, Biotechnology, Call Center

Status

Public (CTXR)

Website

www.citiuspharma.com

LinkedIn

Company page

Recent activity at Citius Pharmaceuticals, Inc.

• Aug 05, 2026: SEC 8-K (8.01): On August 5, 2026, Citius Pharmaceuticals, Inc.'s wholly-owned subsidiary, Citius Oncology, Inc., issued a press release regarding the growing number of institutional accounts ordering LYMPHIR®. This event signifies an important sales milestone for the company as it expands its market presence and aligns with strategic growth objectives. The date of the announcement is pivotal as it reflects the company’s ongoing efforts to enhance relationships with key institutional customers.
• Jun 01, 2026: SEC 8-K (8.01): On June 1, 2026, Citius Pharmaceuticals, Inc.'s wholly-owned subsidiary, Citius Oncology, Inc., issued a press release detailing the presentation of clinical data at the Annual Meeting of the American Society of Clinical Oncology. This event reflects significant advancements in their oncology research, potentially influencing future treatment protocols. The attached press release, found in Exhibit 99.1, contains further specifics about the findings presented. This announcement is crucial for investors and stakeholders as it highlights ongoing developments and the company's commitment to research in cancer treatment.
• May 08, 2026: SEC 8-K (1.01):
• Apr 29, 2026: SEC 8-K (8.01): On April 29, 2026, Citius Oncology, Inc. announced through a press release the initial shipment of LYMPHIR™ (denileukin diftitox-cxdl) to Europe, facilitated by one of its regional distribution partners. This marks a significant step in the commercialization of LYMPHIR™, reflecting the company's strategic intent to expand its market presence in Europe. The press release is included as Exhibit 99.1 of the filing, indicating ongoing developments related to their product distribution. The implications of this initial shipment may enhance Citius Oncology's revenue streams and strengthen partnerships within the European market.
• Apr 24, 2026: SEC 8-K (1.01): On April 23, 2026, Citius Pharmaceuticals, Inc. entered into a securities purchase agreement with institutional investors for a registered direct offering of 4,730,457 shares of common stock at $0.985 per share and pre-funded warrants to purchase up to 345,686 shares at an exercise price of $0.0001. Concurrently, the Company will sell warrants for up to 5,076,143 shares with an exercise price of $0.86, exercisable immediately and valid for five years. These transactions rely on exemptions from registration under the Securities Act, and significant terms include a Beneficial Ownership Limitation preventing holders from exceeding 4.99% of the common stock post-exercise. The Offering reflects the Company’s strategic approach to raise capital and potentially support its growth initiatives.
• Mar 31, 2026: SEC 8-K (8.01): On March 31, 2026, Citius Oncology, Inc., a majority-owned subsidiary of Citius Pharmaceuticals, announced a commercial update regarding the launch of its cancer treatment, LYMPHIR™ (denileukin diftitox-cxdl), in the U.S. This press release informs stakeholders about the current status and progress of the product launch, which is a significant event for the company as it expands its market presence. A copy of the press release is included as Exhibit 99.1.
• Mar 10, 2026: SEC 8-K (8.01): On March 10, 2026, Citius Oncology, Inc. announced positive topline results from a Phase 1 clinical trial conducted by University of Pittsburgh investigators. The trial evaluated the effectiveness of LYMPHIR™ in combination with pembrolizumab (KEYTRUDA ®) for treating patients with recurrent or refractory gynecologic cancers, including ovarian and endometrial malignancies. This significant development suggests potential advancements in treatment options for these cancer types, providing hope for patients affected by these conditions. The communication was issued via a press release that is attached as Exhibit 99.1.
• Mar 04, 2026: SEC 8-K (8.01): On March 4, 2026, Citius Oncology, Inc., a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTOR), issued a press release regarding the positive topline safety and efficacy results from a Phase 1 trial. This trial evaluated LYMPHIR™ (E7777, denileukin diftitox cxdl) administered prior to commercial CD19 directed CAR T therapy in patients suffering from high risk relapsed or refractory diffuse large B cell lymphoma (DLBCL). The announcement is significant as it suggests potential advancements in treatment options for this challenging type of cancer. The press release is attached as Exhibit 99.1.
• Dec 23, 2025: SEC 8-K (2.02): On December 23, 2025, Citius Pharmaceuticals, Inc. reported its results of operations for the full fiscal year 2025, as detailed in a press release. The press release, which is included as Exhibit 99.1, provides insights into the company's financial performance but does not specify financial amounts within the filing. This event highlights the company's financial condition and operational results, which are pertinent information for investors. The disclosure is important for assessing the company's ongoing business performance.
• Dec 01, 2025: SEC 8-K (8.01): On December 1, 2025, Citius Oncology, Inc., a majority-owned subsidiary of Citius Pharmaceuticals, announced the commercial launch of LYMPHIR™, a novel IL-2 receptor-directed fusion protein. This product has been approved by the U.S. Food and Drug Administration for treating adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma, following at least one prior systemic therapy. The launch represents a significant advancement in treatment options for this patient population and is aimed at addressing unmet medical needs. The announcement is accompanied by a press release, which is included as Exhibit 99.2.

Citius Pharmaceuticals, Inc. funding history

Leadership

• Myron Holubiak, Executive Officer, Director
• Leonard Mazur, Executive Officer, Director
• Suren Dutia, Director
• Carol Webb, Director
• William Kane, Director
• Howard Safir, Director
• Eugene Holuka, Director

Verified email and direct lines for Citius Pharmaceuticals, Inc.’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Citius Pharmaceuticals, Inc. in the news

• Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - PR Newswire (Aug 14, 2026)
• Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update - PR Newswire (May 15, 2026)
• Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ - PR Newswire (Feb 13, 2026)
• Citius Pharmaceuticals to Participate in October 2026 Investor Conferences - PR Newswire (Oct 12, 2026)
• Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules - PR Newswire (Apr 24, 2026)
• Citius Pharmaceuticals to Participate in September 2026 Investor Conferences - PR Newswire (Sep 03, 2026)
• Citius Oncology Ships First International Order of LYMPHIR™ to Europe - PR Newswire (Apr 29, 2026)
• Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. - PR Newswire (Aug 12, 2024)

Companies similar to Citius Pharmaceuticals, Inc.

• ISOThrive · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical
• vTv Therapeutics Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical
• Longboard Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical
• Milestone Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical
• Satsuma Pharmaceuticals, Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical

About Citius Pharmaceuticals, Inc.: questions and answers

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy